MIA, human recombinant protein
Melanoma-derived growth regulatory protein precursor, Cartilage-derived retinoic acid-sensitive prot
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q16674 |
---|---|
Calculated MW | 12.2 kDa |
Gene ID | 8190 |
---|---|
Gene Symbol | MIA |
Other Names | Melanoma-derived growth regulatory protein precursor, Cartilage-derived retinoic acid-sensitive protein, CD-RAP, MIA, Melanoma inhibitory activity protein |
Gene Source | Human |
Source | E. coli |
Assay&Purity | SDS-PAGE; ≥98% |
Assay2&Purity2 | HPLC; ≥98% |
Recombinant | Yes |
Application Notes | Reconstitute in H₂O to a concentration of 0.1-1.0 mg/ml. The solution can then be diluted into other aqueous buffers |
Format | Lyophilized protein |
Storage | -20°C; Sterile filtered and lyophilized with no additives |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
MIA is the first discovered member of a family of secreted cytokines termed the MIA/OTOR family. The four known members of this family; MIA, MIA2, OTOR and TANGO each contain a Src homology-3 (SH3)-like domain. MIA is an autocrine growth regulatory protein secreted from chondrocytes and malignant melanoma cells that promotes melanoma metastasis by binding competitively to fibronectin and laminin in a manner that results in melanoma cell detachment from the extraCellular matrix in vivo. Elevated levels of MIA may represent a clinically useful marker for diagnosis of melanoma metastasis as well as a potential marker for rheumatoid arthritis. Recombinant human MIA is a 12.2 kDa globular protein containing 108 amino acid residues including two intramolecular disulfide bonds.
References
Blesch A.,et al.Cancer Res. 54:5695-5701(1994).
Bosserhoff A.-K.,et al.J. Biol. Chem. 271:490-495(1996).
Hau P.,et al.J. Invest. Dermatol. 119:562-569(2002).
Kalnine N.,et al.Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
Ebert L.,et al.Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.